Drugs / ATG (rabbit)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00278564 | Sep 2005 → Jul 2016 | myopathy | Northwestern University | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06769568 | Jan 2025 → Sep 2028 expected | aplastic anemia, disease related to hematopoietic stem cell transplant | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01104025 | Apr 2010 → Nov 2015 | hemophagocytic syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00424489 Background | Feb 2002 → Jun 2016 | myasthenia gravis | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03849651 Background | Jan 2019 → Aug 2024 overdue | Hodgkins lymphoma, T-cell and NK-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia +3 | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG(rabbit) | “ATG ( rabbit ) 2 mg / kg / d-5” NCT06769568 ↗ |
| Action | Deplete | “ATG (a protein that kills the immune cells that are thought to be causing this disease)” NCT00278564 ↗ |
| Modality | Protein / enzyme biologic | “ATG (a protein that kills the immune cells that are thought to be causing this disease)” NCT00278564 ↗ |
| Route | Intravenous | “will be given IV over 10 hours” NCT00278564 ↗ |